Paragon 28 provides innovative orthopedic solutions, procedural approaches and instrumentation covering a wide range of foot and ankle ailments including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD), flatfoot, Charcot foot and orthobiologics. The global market for implants and devices used in foot and ankle procedures is projected to grow at approximately 7% annually to reach $6.9 billion by 2028, representing the fastest-growing market within orthopedics.
Cyborg Score Rationale
Established in 2010, Paragon 28 has an extensive suite of surgical offerings and product systems spanning all major foot and ankle segments, including fracture and trauma, deformity correction and joint replacement. Strategic acquisition by Zimmer Biomet positions the business for significant scale and market expansion, though post-acquisition integration execution will be critical.
Top Insights
The foot and ankle segment is one of the highest growth specialties in musculoskeletal care.
Since its inception, Paragon 28 has been singularly focused on bringing to market innovative solutions to address areas of unmet need in the foot and ankle segment.
Primary competitors in the lower extremities market include multinational companies such as Stryker, Arthrex, Smith & Nephew, Johnson & Johnson and Zimmer Biomet, as well as companies with one or a limited number of foot and ankle products.
The transaction enhances Zimmer Biomet's foot and ankle offerings by integrating Paragon 28's advanced technology platform with existing joint replacement and trauma portfolios, and creates a dedicated sales channel for foot and ankle solutions.
Named Competitors
Arthrex — Orthopedic and sports medicine devices
Stryker — Orthopedic and surgical equipment
Smith & Nephew — Orthopedic and wound management devices
DePuy Synthes — Orthopedic implants and trauma devices
Treace Medical Concepts — Foot and ankle orthopedic devices
Recent Developments
(January 2025) Zimmer Biomet announced definitive agreement to acquire Paragon 28 for $13.00 per share in cash plus contingent value rights of up to $1.00 per share
(April 2025) Zimmer Biomet completed acquisition of Paragon 28; shares ceased trading and delisted from NYSE
Open the full interactive Paragon 28, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.